Hans T. Schambye, MD PhD

CEO

Hans Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. Previously, Hans served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.

Anders Pedersen

COO

Anders Pedersen joined Galecto Biotech in 2013 as Chief Operating Officer. Here he is responsible for managing the project portfolio and the collaboration with service providers. Previously, he served as senior vice president of development at CMC Biologics. Anders has more than 25 years of experience in the biopharmaceutical industry. His background experience is in process development and discovery of biopharmaceuticals. Prior to CMC Biologics, he spent 13 years at Novo Nordisk. He was a cofounder of ProFound Pharma, which was later acquired by Maxygen. Anders also served as vice president of project and portfolio management at Life Cycle Pharma and Chief Operting Officer at Recepticon. He has a degree in Chemical Engineering from Danish Technical University in Copenhagen.

Paul Ford, MB BS, PhD

Chief Medical Officer

Paul Ford is an experienced clinical pulmonologist with significant knowledge of research and translational medicine in the pharmaceutical industry. He has headed several projects from Proof of Concept through to Clinical Trial Phase IIb and has also been working with medical device start-ups. Moreover, Paul has functioned as a Respiratory Consultant Physician. Paul has an MB BS from University of London and completed his PhD in 2003 in cellular biology from the University of London. Since 1993, Paul has been a member of the Royal College of Physicians. Previous experience includes positions as Clinical Director of Innovo Medical, Director and Senior Translational Medicine Expert at Novartis Institutes for Biomedical Research (NIBR), MRC funded Senior Clinical Research Fellow, Imperial College & Royal Brompton, Respiratory Consultant at Nottingham University Hospital and Medical Advisor for Boehringer Ingelheim, UK.

Dorrit Andersen, MSc (Pharm)

Director, Regulatory

Dorrit Andersen is responsible for the regulatory affairs activities as a consultant. She has more than 30 years of experience in the biopharmaceutical industry working with global development of pharmaceuticals (quality, clinical and regulatory). Dorrit has previously worked as global regulatory affairs director at Novo Nordisk and before establishing her consultancy business as regulatory affairs manager at Symphogen and Genmab. Prior to Novo Nordisk she was head of regulatory affairs and clinical project manager at Ciba-Geigy DK. Her latest accomplishment as a consultant is the submission and approval of a recombinant protein therapeutic in the USA and EU. Dorrit Andersen holds a degree in pharmacy from the University of Copenhagen.